Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02555397 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
A Phase 1 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02555397: Completed Phase 1 study, sponsored by Henry Ford Health System.
NCT02555397 is a Phase 1 study that has completed, run by Henry Ford Health System. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02555397, a Phase 1 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy in men with locally recurrent prostate cancer after definitive radiotherapy
Interventions
- BIOLOGICAL Ad5-yCD/mutTKSR39rep-hIL12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-08 |
| Est. Completion | 2024-01-22 |
| Phase | Phase 1 |
What the finished NCT02555397 record still lists
NCT02555397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Ad5-yCD/mutTKSR39rep-hIL12 is the first listed.
NCT02555397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02555397 about?
NCT02555397 is a clinical study titled "Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer". The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy in men with locally recurrent prostate cancer after definitive radiotherapy
What is the current status of trial NCT02555397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-08. Estimated completion is 2024-01-22.
What interventions are being tested in trial NCT02555397?
The interventions under investigation include: Ad5-yCD/mutTKSR39rep-hIL12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02555397?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02555397's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia